Nearly all of Latin America was excluded from the deal, sparking concern the world is missing a critical opportunity to stop ...

In the PURPOSE 2 trial, lenacapavir offered almost complete protection to cisgender men, transgender women, transgender men, ...

Colombia hosts the largest population of migrants and refugees from Venezuela, where more than 7.7 million have left since ...

Matías Tarnopolsky will become president and CEO of the New York Philharmonic on Jan. 1, after four years heading the ...

Scientists have developed Lenacapavir, a twice-yearly injection that cuts HIV infection risk by 96% in groundbreaking trials.

In Argentina, patients and medical professionals are alarmed by President Javier Milei's proposed spending cuts that are affecting HIV/AIDS treatment and prevention. The austerity measures, aimed at ...

It’s been called the closest the world has ever come to a vaccine against AIDS. The twice-yearly shot was 100% effective in ...

Lenacapavir, a new twice-yearly injection, offers 96% HIV prevention efficacy, surpassing daily oral PrEP. For oral ...

Current health news highlights include Sanofi's $1 billion investment in a Beijing insulin site, New Zealand's poultry export ...